Guselkumab is the first and only interleukin-23 inhibitor that offers both subcutaneous and intravenous induction options for ...
The following is a summary of "Treatment Sequencing in Inflammatory Bowel Disease: Towards Clinical Precision Medicine," published in the March 2025 issue of Best Practice & Research Clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback